Turning the Tide against Herpes Zoster in Rheumatoid Arthritis Patients Treated with JAK InhibitorsArticle Published on 2024-07-292024-09-05 Journal: Journal of Clinical Medicine [Category] update2024, [키워드] herpes zoster Janus kinase inhibitor Safety Vaccine [DOI] 10.3390/jcm13154423 PMC 바로가기 [Article Type] Article
Association Between the Dose of Tofacitinib and Risk of Herpes Zoster in Patients With Rheumatoid Arthritis: Analysis of Japanese Adverse Drug Event Report DataInternal Medicine Published on 2024-06-142024-09-05 Journal: Cureus [Category] update2024, [키워드] dose of tofacitinib herpes zoster Janus kinase inhibitor Japanese Adverse Drug Event Report database rheumatoid arthritis [DOI] 10.7759/cureus.62372 PMC 바로가기 [Article Type] Internal Medicine
Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with UpadacitinibOriginal Report Published on 2024-05-062024-09-05 Journal: Acta dermato-venereologica [Category] update2024, [키워드] atopic dermatitis ITCH Janus kinase inhibitor skin clearance Treat-to-target Upadacitinib [DOI] 10.2340/actadv.v104.18452 PMC 바로가기 [Article Type] Original Report
Electrochemical Behavior of Janus Kinase Inhibitor Ruxolitinib at a Taurine-Electropolymerized Carbon Paste Electrode: Insights into Sensing Mechanismsarticle Published on 2024-04-062024-09-05 Journal: ACS applied bio materials [Category] update2024, [키워드] Electrochemical oxidation electropolymerization Janus kinase inhibitor ruxolitinib Taurine [DOI] 10.1021/acsabm.4c00186 PMC 바로가기 [Article Type] article
Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal InfectionsReview Published on 2024-03-312024-09-05 Journal: Journal of Fungi [Category] update2024, [키워드] Fedratinib Histoplasmosis Invasive fungal infection Janus kinase inhibitor myelofibrosis ruxolitinib [DOI] 10.3390/jof10040264 PMC 바로가기 [Article Type] Review
Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in Chinaarticle Published on 2023-10-182024-09-02 Journal: Arthritis Research & Therapy [Category] 대상포진, [키워드] Biologic therapy Janus kinase inhibitor juvenile dermatomyositis refractory Tofacitinib [DOI] 10.1186/s13075-023-03170-z PMC 바로가기 [Article Type] article
Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III studyarticle Published on 2023-09-182024-09-02 Journal: Arthritis Research & Therapy [Category] 대상포진, [키워드] ankylosing spondylitis biologic Inadequate response Janus kinase inhibitor Open-label extension refractory tumor necrosis factor Upadacitinib [DOI] 10.1186/s13075-023-03128-1 PMC 바로가기 [Article Type] article
A case series on tofacitinib-induced weight gainCase Series Published on 2023-09-112024-09-04 Journal: Indian journal of pharmacology [Category] 대상포진, [키워드] Autoimmune disease Janus kinase inhibitor Tofacitinib weight gain [DOI] 10.4103/ijp.ijp_158_23 PMC 바로가기 [Article Type] Case Series
Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritisRheumatology Published on 2023-07-202024-09-04 Journal: The Korean journal of internal medicine [Category] 대상포진, [키워드] comparative effectiveness research Janus kinase inhibitor rheumatoid arthritis Safety tumor necrosis factor inhibitors [DOI] 10.3904/kjim.2022.369 PMC 바로가기 [Article Type] Rheumatology
Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerationsArticle Published on 2023-04-282024-09-04 Journal: The journal of allergy and clinical immunology. In [Category] 대상포진, [키워드] abrocitinib atopic dermatitis Baricitinib biologics cytokine signaling Dupilumab eczema interleukin-13 Interleukin-4 Janus kinase inhibitor lebrikizumab nemolizumab tralokinumab Upadacitinib [DOI] 10.1016/j.jaip.2023.03.011 PMC 바로가기 [Article Type] Article